Search
Browse
Statistics
Feeds

Biological advances and current challenges for pediatric rhabdomyosarcoma

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB
[thumbnail of Supplementary Material] Other (Supplementary Material)
86kB

Item Type:Article
Title:Biological advances and current challenges for pediatric rhabdomyosarcoma
Creators Name:Hebron, Katie E., Odeniyide, Patience, Wei, Yun, Gryder, Berkley E., Barr, Frederic G., Casey, Dana L., Chen, Eleanor Y., Crompton, Brian D., Dela Cruz, Filemon S., Durbin, Adam D., Ford, Heide L., Gatz, Susanne A., Hatley, Mark E., Henssen, Anton G., Hettmer, Simone, Houghton, Peter J., Kendall, Genevieve C., Khan, Javed, Lupo, Philip J., Patel, Anand G., Pomella, Silvia, Rota, Rossella, Schito, Marco, Schoot, Reineke A., Shern, Jack F., Stanton, Benjamin Z., Stewart, Elizabeth A., Swindlehurst, Cathy A., Thomas, Craig J., Vakoc, Christopher R., Vaseva, Angelina V., Venkatramani, Rajkumar, Wexler, Leonard H., Yustein, Jason T., Hammond, Sharon, Heske, Christine M., Langenau, David M., Linardic, Corinne M., Ignatius, Myron S. and Yohe, Marielle E.
Abstract:Despite comprehensive and multi-modal therapy, outcomes for children and adolescents with rhabdomyosarcoma (RMS) have plateaued over the past four decades. This is not for a lack of progress in the basic and translational studies of RMS. Indeed, advances in animal models and/or patient tissue sample acquisition and analysis have improved our understanding of RMS biology. Large-scale sequencing efforts have generated transcriptomic, genomic, and epigenomic datasets that highlight the heterogeneity of RMS and have the potential to improve prognostication and the application of precision medicine in patients with RMS. However, few of these discoveries have been clinically translated, and limitations to the accessibility, uniformity, and application of these new models and datasets hinder their utility. Here, we discuss how advances in understanding RMS biology, optimization of preclinical models, and strategies for translating basic science discoveries to the clinic can potentially improve outcomes for patients with RMS.
Keywords:Pediatric Sarcoma, Cells of Origin, Animal Models, Tumor Heterogeneity, Skeletal Muscle Malignancy
Source:Cancers
ISSN:2072-6694
Publisher:MDPI
Volume:18
Number:6
Page Range:888
Number of Pages:1
Date:March 2026
Official Publication:https://doi.org/10.3390/cancers18060888

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library